Business Context and Reporting Period
Company: Pluristem Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 26, 2012
Principal Executive Offices: Haifa, Israel
This filing reports the entry into a Material Definitive Agreement regarding an "At Market Issuance Sales Agreement" (Sales Agreement) with MLV & Co. LLC to facilitate the sale of common stock.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing focuses exclusively on the authorization of a potential equity offering.
- Maximum Offering Size: Up to $95,000,000 in aggregate offering price.
- Commission Rate: Up to 3.0% of gross proceeds payable to the sales agent (MLV).
- Registration Basis: Sales will be made under a previously filed and effective shelf registration statement on Form S-3 (File No. 333-177009).
Material Changes
The material change reported is the execution of the Sales Agreement on December 26, 2012. This agreement grants Pluristem the option, but not the obligation, to sell shares of its common stock through MLV as a sales agent. The agreement allows for sales via "at-the-market" offerings on The NASDAQ Capital Market or through market makers, subject to Pluristem's instructions regarding price, time, and size limits.
Guidance, Outlook, and Risks
Outlook and Obligations: Pluristem is not obligated to make any sales under the agreement. No assurance is provided that any shares will be sold, nor regarding the price, amount, or timing of potential sales.
Termination Terms:
- Either party may terminate the agreement at any time upon 10 days' notice.
- MLV may terminate in certain specified circumstances.
- The agreement automatically terminates upon the sale of all common stock subject to the agreement.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the disclosure does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the current market price of Pluristem common stock to assess potential dilution from a $95 million offering.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific conditions and termination rights.
- Confirm the status of the underlying Form S-3 shelf registration (File No. 333-177009).
- Monitor future filings for actual sales activity, as no sales are guaranteed under this agreement.